Therefore, the combination of CAR T-cell therapies with pharmacological co-interventions or the use of genetically enhanced CAR T-cell products—as exemplified in this study—may be a preferable strategy towards more efficacious and tolerable cellular therapies for patients with TP53-mutant myeloid neoplasms. Here, TP53 is linked to myeloid neoplasm.